Combining lenalidomide (Revlimid) with rituximab (Rituxan) significantly improved progression-free survival (PFS) compared with rituximab alone for the treatment of patients with relapsed/refractory indolent lymphoma, meeting the primary endpoint of the phase III AUGMENT trial.
In results presented at the 2018 ASCO Annual Meeting, the R2
combination showed similar efficacy compared with rituximab plus chemotherapy, which failed to satisfy the primary endpoint for the phase III RELEVANCE trial for patients with untreated follicular lymphoma; however, the chemotherapy-free regimen had a more favorable safety profile, making it a potential first-line option.
After 120 weeks, R2
showed a complete remission (CR) or unconfirmed CR (CRu) rate of 48% compared with 53% for rituximab/chemotherapy (P
The objective response rate (ORR) with the R2
regimen was 84% compared with 89% for rituximab/chemotherapy. The 3-year duration of response was 77% with R2
compared with 74% for rituximab/chemotherapy.
... to read the full story